Suppr超能文献

比较经皮冠状动脉介入治疗的急性 ST 段抬高型心肌梗死患者冠状动脉内与静脉内替罗非班的疗效。

Comparison of intracoronary versus intravenous tirofiban in acute ST-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention.

机构信息

Department of Cardiology, The first hospital of QinHuangDao, QinHuangDao.

Department of Critical Care Medicine, People's Hospital of Yangjiang, Yangjiang.

出版信息

Coron Artery Dis. 2022 Nov 1;33(7):547-552. doi: 10.1097/MCA.0000000000001177. Epub 2022 Aug 9.

Abstract

OBJECTIVE

This study aimed to investigate the effect of intracoronary (IC) tirofiban compared to intravenously administered tirofiban in STEMI patients treated with PPCI.

METHODS

This study included 180 STEMI patients who were underwent PPCI. Patients were randomized into an IC group ( n = 90) and intravenous (IV) group ( n = 90). During the procedure, the both groups were administered IC or IV injections of tirofiban, respectively, followed by an IV infusion of tirofiban for 24 hours. Changes in TIMI flow grading, TMP grade 3, Sum-STR two hours after the operation, the number of thrombus aspirations during the operation, myocardial enzyme, inflammatory factors,cardiac functional parameters, MACE and bleeding were investigated.

RESULTS

Following treatment, TIMI flow grading and TMP grade 3 were improved in the IC tirofiban compared to the IV group ( P = 0.022 and P = 0.014, respectively). Additionally, the Sum-STR two hours after operation, the incidence of MACEs, levels of AST, CRP, ESR, and TNI in the IC group was improved, compared with the IV group (all P < 0.05). Furthermore. Cardiac function including CO and LVEF were significantly improved in the IC group 6 months after discharge.

CONCLUSION

This study found that IC administration of tirofiban in patients with STEMI who underwent PPCI improved TIMI, TMP flow and cardiac function 6 months after discharge, and reduced CRP, ESR, and TNI. However, the incidence of bleeding between the two groups was comparable. These findings suggest that IC administration should be applied in certain acute STEMI patients.

摘要

目的

本研究旨在探讨经皮冠状动脉介入治疗(PPCI)中冠状动脉内(IC)比伐芦定与静脉内给予比伐芦定对 ST 段抬高型心肌梗死(STEMI)患者的影响。

方法

本研究纳入了 180 例接受 PPCI 的 STEMI 患者。患者随机分为 IC 组(n = 90)和静脉(IV)组(n = 90)。在手术过程中,两组分别给予 IC 或 IV 比伐芦定注射,随后静脉输注比伐芦定 24 小时。观察手术前后 TIMI 血流分级、TMP 分级 3、术后 2 小时 Sum-STR、术中血栓抽吸次数、心肌酶、炎症因子、心功能参数、主要不良心血管事件(MACE)和出血情况的变化。

结果

治疗后,IC 比伐芦定组 TIMI 血流分级和 TMP 分级 3 较 IV 组改善(P = 0.022 和 P = 0.014)。此外,IC 组术后 2 小时 Sum-STR、MACE 发生率、AST、CRP、ESR 和 TNI 水平较 IV 组改善(均 P < 0.05)。此外,IC 组出院后 6 个月心脏功能包括 CO 和 LVEF 显著改善。

结论

本研究发现,PPCI 治疗的 STEMI 患者 IC 给予比伐芦定可改善 TIMI、TMP 血流和心脏功能 6 个月后,并降低 CRP、ESR 和 TNI。然而,两组间出血发生率相当。这些发现表明,IC 给药应应用于某些急性 STEMI 患者。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验